인크레틴계 약제 시장 : 약제 클래스별, 투여 경로별, 유통 채널별 - 세계 기회 분석과 산업 예측(2023-2032년)

Incretin-Based Drugs Market By Drug Class, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,992,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,391,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

인크레틴계 약제 시장은 의약품 부문로부터의 시장 수요의 증가에 의해 2023-2032년 7.9%의 대폭적인 성장률을 기록할 가능성이 높습니다.

2형 당뇨병 관리에서 인크레틴의 작용을 강화하기 위해 DPP-4 억제제와 GLP-1 유사체를 사용하는 것이 약제학적 접근법으로, DPP-4 억제제는 DPP-4의 활성을 억제하는 방식으로 작용합니다. 이 약물은 순환하는 글루카곤 유사 펩티드(GLP-1)와 위 억제 펩티드(GIP)의 수치를 증가시킵니다. 이 호르몬은 인슐린 분비와 포도당 조절에 오랜 시간 동안 작용합니다. 한편, 합성 GLP-1 제제는 DPP-4의 분해에 저항하는 GLP-1 운송체입니다. 합성 GLP-1 약물은 천연 GLP-1의 작용을 모방하여 작용합니다. 이 약물은 인슐린 분비를 증가시키고, 글루카곤 분비를 억제하고, 위 배출을 지연시키고, 식욕을 감소시킵니다.

인크레틴계 약제 시장의 성장은 주로 전 세계에서 2형 당뇨병 환자가 많기 때문인데, 2형 당뇨병은 혈당이 너무 높고 인슐린이 충분히 분비되지 않는 상태입니다. 전 세계에서 비만이 증가함에 따라 2형 당뇨병 환자 수가 증가하는 추세입니다. 현재 2형 당뇨병 치료에는 인크레틴 계열의 약물이 사용되고 있습니다. 이 약들은 다양한 방식으로 당대사를 조절하고 저혈당을 동반하며, 체중에는 영향을 미치지 않거나 체중 감소를 촉진하지 않습니다. 따라서 이 질환의 치료에 큰 수요가 있으며, 인크레틴계 약제 시장의 성장을 촉진하고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 2형 당뇨병의 유병률 상승
    • 시장에서의 최근 제품 승인과 제품 출시
    • 인크레틴계 약물 요법에서의 최근 진보
  • 억제요인
    • 인크레틴계 약제의 고비용
    • 약에 관한 엄격한 규제
  • 기회
    • 인크레틴계 약제 연구개발의 급증

제4장 인크레틴계 약제 시장 : 약제 클래스별

• 개요
• GLP-1 수용체 작용제
• DPP-4 저해제

제5장 인크레틴계 약제 시장 : 투여 경로별

• 개요
• 비경구제
• 경구제

제6장 인크레틴계 약제 시장 : 유통경로별

• 개요
• 병원 약국
• 드러그스토어 및 소매 약국
• 온라인 프로바이더

제7장 인크레틴계 약제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Eli Lilly and Company.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Ltd.
• AstraZeneca plc
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Lupin
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Novartis AG

KSA

영문 목차

영문목차

The incretin-based drugs market is likely to experience a significant growth rate of 7.9% from 2023-2032 owing to increasing market demand from pharmaceuticals sector - Allied Market Research

To enhance the action of incretins in managing type 2 diabetes, pharmaceutical approaches include the use of DPP-4 inhibitors and GLP-1 analogues. The DPP-4 inhibitors work by blocking DPP-4 activity. These drugs increase the levels of circulating glucagon-like peptides (GLP-1) and gastric inhibitory peptide (GIP). These hormones have a longer-lasting effect on insulin secretion and glucose regulation. On the other hand, synthetic GLP-1 drugs are GLP-1 transporters that are more tolerant to DPP-4 degradation. They work by mimicking the action of natural GLP-1. These drugs increase insulin release, inhibit glucagon secretion, slow gastric emptying, and reduce appetite.

The growth of incretin-based drugs market is mainly attributed to the high prevalence of type 2 diabetes population around the globe. Type 2 diabetes is a condition in which blood sugar levels are too high and the body is not able to produce enough insulin. The number of people with type 2 diabetes is on the rise, due to the rise in obesity around the world. Diabetes mellitus (Type 2) is currently treated using incretin-based drugs. These drugs control glucose metabolism in a variety of ways, are associated with low levels of hypoglycemia, and either do not affect body weight or do not stimulate weight loss. Thus have a huge demand in the treatment of this condition, which propels the growth of the incretin-based drugs market.

In addition, incretin-based drugs have shown promising results in weight loss or weight neutrality. This makes them attractive to a wider patient base interested in obesity management. Furthermore, ongoing R&D efforts to enhance the effectiveness, safety, and delivery mechanisms of the incretin-based therapies have also contributed to market expansion. The growing knowledge of the biology behind incretin and its impact on various metabolic disorders continue to drive innovation. This is anticipated to drive the market for incretin-based drugs in coming years.

However, the high cost of the treatment and regulatory challenges may hamper market growth to some extent. Incretin based drugs are usually more expensive than traditional diabetes drugs. Cost becomes a major issue, especially in areas where healthcare costs are high, which may limit access to these drugs. Also, the market is affected by stringent regulations and approval procedures by regulatory bodies such as the Food and Drug Administration (FDA) in the U.S. and the European Medicines Agency (EMA) in Europe. Delays or complexity in the approval of new drugs or indications may impede market growth.

The incretin-based drugs market is segmented on the basis of drug class, route of administration, distribution channel, and region. On the basis of drug class, the market is divided into GLP-1 receptor agonists and DPP-4 inhibitors. On the basis of route of administration, the market is classified into oral and parenteral. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major players profiled in this report are Eli Lilly and Company., Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, Sun Pharmaceutical Industries Ltd., Lupin, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca plc and Takeda Pharmaceutical Company Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the incretin-based drugs market analysis from 2022 to 2032 to identify the prevailing incretin-based drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the incretin-based drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global incretin-based drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Brands Share Analysis
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Import Export Analysis/Data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• List of customers/consumers/raw material suppliers- value chain analysis
• Market share analysis of players at global/region/country level
• Per Capita Consumption Trends
• Product Consumption Analysis
• Reimbursement Scenario
• SWOT Analysis
• Volume Market Size and Forecast

Key Market Segments

By Drug Class

• GLP-1 receptor agonists
• DPP-4 inhibitors

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Eli Lilly and Company.
• Takeda Pharmaceutical Company Ltd.
• Lupin
• Novartis AG
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH
• Sanofi
• Novo Nordisk A/S
• AstraZeneca plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rising prevalence of type-2 diabetes
    • 3.4.1.2. Recent product approvals and product launches in the market
    • 3.4.1.3. Recent advancement in Incretin-Based Pharmacotherapies
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of incretin-based drugs
    • 3.4.2.2. Stringent regulations related to medications
  • 3.4.3. Opportunities
    • 3.4.3.1. Surge in research and development in incretin-based drugs

CHAPTER 4: INCRETIN-BASED DRUGS MARKET, BY DRUG CLASS

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. GLP-1 receptor agonists
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. DPP-4 inhibitors
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: INCRETIN-BASED DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Parenteral
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Oral
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: INCRETIN-BASED DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug Stores and Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: INCRETIN-BASED DRUGS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Drug Class
  • 7.2.3. Market size and forecast, by Route of Administration
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Drug Class
    • 7.2.5.1.2. Market size and forecast, by Route of Administration
    • 7.2.5.1.3. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Drug Class
    • 7.2.5.2.2. Market size and forecast, by Route of Administration
    • 7.2.5.2.3. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Drug Class
    • 7.2.5.3.2. Market size and forecast, by Route of Administration
    • 7.2.5.3.3. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Drug Class
  • 7.3.3. Market size and forecast, by Route of Administration
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Drug Class
    • 7.3.5.1.2. Market size and forecast, by Route of Administration
    • 7.3.5.1.3. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Drug Class
    • 7.3.5.2.2. Market size and forecast, by Route of Administration
    • 7.3.5.2.3. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Drug Class
    • 7.3.5.3.2. Market size and forecast, by Route of Administration
    • 7.3.5.3.3. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Drug Class
    • 7.3.5.4.2. Market size and forecast, by Route of Administration
    • 7.3.5.4.3. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Drug Class
    • 7.3.5.5.2. Market size and forecast, by Route of Administration
    • 7.3.5.5.3. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Drug Class
    • 7.3.5.6.2. Market size and forecast, by Route of Administration
    • 7.3.5.6.3. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Drug Class
  • 7.4.3. Market size and forecast, by Route of Administration
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Drug Class
    • 7.4.5.1.2. Market size and forecast, by Route of Administration
    • 7.4.5.1.3. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Drug Class
    • 7.4.5.2.2. Market size and forecast, by Route of Administration
    • 7.4.5.2.3. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Drug Class
    • 7.4.5.3.2. Market size and forecast, by Route of Administration
    • 7.4.5.3.3. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Drug Class
    • 7.4.5.4.2. Market size and forecast, by Route of Administration
    • 7.4.5.4.3. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Drug Class
    • 7.4.5.5.2. Market size and forecast, by Route of Administration
    • 7.4.5.5.3. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Drug Class
    • 7.4.5.6.2. Market size and forecast, by Route of Administration
    • 7.4.5.6.3. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Drug Class
  • 7.5.3. Market size and forecast, by Route of Administration
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Drug Class
    • 7.5.5.1.2. Market size and forecast, by Route of Administration
    • 7.5.5.1.3. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Drug Class
    • 7.5.5.2.2. Market size and forecast, by Route of Administration
    • 7.5.5.2.3. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Drug Class
    • 7.5.5.3.2. Market size and forecast, by Route of Administration
    • 7.5.5.3.3. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Drug Class
    • 7.5.5.4.2. Market size and forecast, by Route of Administration
    • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Eli Lilly and Company.
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Merck & Co., Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Takeda Pharmaceutical Company Ltd.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. AstraZeneca plc
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Sanofi
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Sun Pharmaceutical Industries Ltd.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Lupin
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Novo Nordisk A/S
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Boehringer Ingelheim International GmbH
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Novartis AG
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료